B-CELL LYMPHOMA

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to seek out and destroy cancer cells while sparing healthy ones. The study aims to fin…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests an experimental pill called LP-168 in adults with B-cell lymphoma that has returned or not responded to standard treatments. The main goals are to find the safest dose and check if the drug shrinks tumors. About 200 participants will take the drug by mouth, and r…

This study tests whether combining two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take the drugs and be monitored for tumor response and side effects. The goal is to contr…

This study tests whether combining two treatments, axicabtagene ciloleucel and glofitamab, can help control large B cell lymphoma that has returned or not responded to initial therapy. About 40 adults with this type of lymphoma will receive the combination as a second-line treatm…

This early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell lymphoma that has not responded to prior treatments. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 …

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to standard therapy. Participants receive donor immune cells (NK cells) that are engineered to better target cancer, along with chemoth…

This early-stage trial tests a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to other treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The study will check if the treatment i…

This study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. About 24 participants will receive the treatment …

This early study tests a new gene therapy (LCAR02) for up to 18 people with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a modified gene to target and attack cancer cells. The main goals are to check safety and see how well the treatment work…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants receive the drugs in cycles, with adjustments based on how well the cancer responds. The goal is to see how many peop…

This study tests a new type of immunotherapy for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to target…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The goal is to find safe doses …

This study tests whether combining zanubrutinib (a pill) with rituximab (an infusion) can control a dangerous immune overreaction called HLH that happens in people with B-cell lymphoma. About 40 adults aged 14-80 will receive the drugs for 4 weeks, along with other medications li…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults with B-cell lymphoma that has returned or hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target a protein called BAFF-R …

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will either get early palliative care or standard care alone. Researchers will track quality …

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…